Jasjot Bhullar, MD
Nephrology · Loma Linda, CANPI 1366602229
Payments from drug & device makers
Across 81 payments — averaging $210.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim International GmbH$15K
- Amgen$404
- Mallinckrodt Hospital Products Inc.$246
- GSK$193
- Mallinckrodt Enterprises LLC$185
- Calliditas Therapeutics US Inc.$183
- plus $767 from 11 others
What the payments were for
- Food & beverage$1,86794%
- Education$1126%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim International GmbH | 19 | $15,055 |
| Amgen(2 entities) | 25 | $404 |
| Mallinckrodt Hospital Products Inc. | 2 | $246 |
| GSK | 6 | $193 |
| Mallinckrodt Enterprises LLC | 7 | $185 |
| Calliditas Therapeutics US Inc. | 2 | $183 |
| Baxter Healthcare | 2 | $181 |
| Akebia Therapeutics Inc | 2 | $146 |
| Novo Nordisk | 1 | $111 |
| Otsuka America Pharmaceutical, Inc. | 5 | $73 |
| AstraZeneca | 1 | $71 |
| Inari Medical, Inc. | 1 | $65 |
| Daiichi Sankyo Inc. | 3 | $43 |
| ANI Pharmaceuticals, Inc. | 1 | $27 |
| OPKO Pharmaceuticals, LLC | 2 | $26 |
| Fresenius USA Marketing, Inc. | 1 | $14 |
| Vifor Pharma, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$17,034 in reported general payments places this provider in the 80th percentile of 1,341 nephrology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 62 | $43,238 |
| Cinacalcet Hcl | 12 | $1,042 |
| Omega-3 Acid Ethyl Esters | 32 | $811 |
| Spironolactone | 64 | $411 |
| Amlodipine Besylate | 73 | $345 |
| Calcitriol | 31 | $324 |
| Lisinopril | 27 | $302 |
| Vitamin D2Ergocalciferol (Vitamin D2) | 46 | $300 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 12 | $210 |
| Losartan Potassium | 53 | $202 |
| Carvedilol | 41 | $183 |
| Allopurinol | 55 | $164 |
| Nifedipine ErNifedipine | 15 | $135 |
| Gabapentin | 14 | $117 |
| Furosemide | 37 | $102 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Loma Linda
- Sayna NorouziLoma Linda$1.7M
- Rafael VillicanaLoma Linda$627K
- Anjay RastogiLos Angeles$6.3M
- Aamir JamalSan Dimas$5.5M
- Mohamed El-ShahawyLos Angeles$4.4M
- Kalpesh PatelCalabasas$3.6M
- Jehad HaggiagiMission Hills$3.6M
- Malvin YanSouth Gate$3.3M
- Sohan DuaNorthridge$3.2M
- Richard LafayetteStanford$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.